Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additional relevant biomarkers to existing tests, but ensuring they are adequately validated and robust for translation into a clinical research setting. The Oncomine Comprehensive Assay v3 has been implemented for use in both translational and clinical research projects including the NCI MATCH trial and shown reproducible and robust results. The newest version of the Oncomine Comprehensive Assay, Oncomine Comprehensive Assay Plus extends the already demonstrated high quality of performance into a larger targeted panel encompassing additional relevant content. Moreover, the extension of the panel allows for the determination of mutational signatures such as Tumour Mutational Burden (TMB) and Microsatellite Instabililty (MSI). This presentation will review our current experience with the Oncomine Comprehensive Assay Plus in the profiling of solid tissues from both formalin fixed paraffin embedded and fresh frozen material for use in the translational research setting.
1. Identifying key performance metrics for choosing the right assay for clinical research studies
2. Understanding the importance of a fluid workflow for integrating new content for precision medicine studies